Bruton's tyrosine kinase inhibition—An emerging therapeutic strategy in immune‐mediated dermatological conditions-Reference-Cited by-同舟云学术

Bruton's tyrosine kinase inhibition—An emerging therapeutic strategy in immune‐mediated dermatological conditions

Published:2022-02-28 Issue:8 Volume:77 Page:2355-2366
ISSN:0105-4538
Container-title:Allergy
language:en
Short-container-title:Allergy

Author:

Mendes‐Bastos Pedro¹^ORCID,Brasileiro Ana²³^ORCID,Kolkhir Pavel⁴⁵⁶^ORCID,Frischbutter Stefan⁴⁶^ORCID,Scheffel Jörg⁴⁶,Moñino‐Romero Sherezade⁴⁶^ORCID,Maurer Marcus⁴⁶^ORCID

Affiliation:

1. Dermatology Center Hospital CUF Descobertas Lisbon Portugal

2. Department of Dermatology Hospital Santo António dos Capuchos Centro Hospitalar Universitário Lisboa Central Lisbon Portugal

3. NOVA Medical School Universidade NOVA de Lisboa Lisbon Portugal

4. Dermatological Allergology, Allergie‐Centrum‐Charité, Department of Dermatology and Allergy, Charité‐Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin Humboldt‐Universität zu Berlin, and Berlin Institute of Health Berlin Germany

5. Division of Immune‐Mediated Skin Diseases I.M. Sechenov First Moscow State Medical University (Sechenov University) Moscow Russia

6. Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology Berlin Germany

Funder

Novartis

Publisher

Wiley

Subject

Immunology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/all.15261

Reference121 articles.

1. AGAMMAGLOBULINEMIA

2. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases

3. Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia

4. Colocalization of X-Linked Agammaglobulinemia and X-Linked Immunodeficiency Genes

5. Mutation of Unique Region of Bruton's Tyrosine Kinase in Immunodeficient XID Mice

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The potential of Bruton’s tyrosine kinase (BTK) inhibitors in the pharmacotherapeutic management of immune and dermatological disease;Expert Opinion on Pharmacotherapy;2024-08-12

2. Efficacy and Safety of Upadacitinib or Elsubrutinib Alone or in Combination for Patients With Systemic Lupus Erythematosus: A Phase 2 Randomized Controlled Trial;Arthritis & Rheumatology;2024-08-07

3. Chronic Inducible Urticaria;Immunology and Allergy Clinics of North America;2024-08

4. A review of TEC family kinases and their inhibitors in the treatment of alopecia areata;Archives of Dermatological Research;2024-07-30

5. Urticaria Beyond Omalizumab: What is Next?;Current Treatment Options in Allergy;2024-07-30